Press room | News



May 26, 2016

Hart-Scott-Rodino Clearance for Global Collaboration between its Subsidiary Heptares Therapeutics and Allergan

Apr 28, 2016

Heptares CSO and Co-founder - Dr Fiona Marshall - Elected as a Fellow of The Academy of Medical Sciences

Apr 25, 2016

Heptares Scientists Solve Structures of GLP-1 and Glucagon Receptors enabling Structure-Based Design for Metabolic Disease

Apr 18, 2016

Heptares and Kymab enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics

Apr 6, 2016

Allergan and Heptares Announce Global R&D and Commercialization Partnership for Novel Treatments in Alzheimer’s and Other Neurological Disorders

Apr 4, 2016

Heptares Joins Pharma Consortium Applying State-of-the-Art Cryo-Electron Microscopy to Advance Structure-Based Drug Discovery

Feb 10, 2016

Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-In-Class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia

Feb 2, 2016

Heptares Launches “ORBIT” Initiative - A New Collaborative Drug R&D Programme for Industry and Academia Focused on G Protein-Coupled Receptors (GPCRs)

Back to top

Other News


© 2012-2016 Heptares Therapeutics